Integrum AB Series B (INTEG-B) - Net Assets

Latest as of June 2026: Skr174.19 Million SEK ≈ $18.75 Million USD

Based on the latest financial reports, Integrum AB Series B (INTEG-B) has net assets worth Skr174.19 Million SEK (≈ $18.75 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr199.15 Million ≈ $21.43 Million USD) and total liabilities (Skr24.96 Million ≈ $2.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Integrum AB Series B (INTEG-B) strategic asset index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr174.19 Million
% of Total Assets	87.47%
Annual Growth Rate	40.04%
5-Year Change	7.68%
10-Year Change	1532.82%
Growth Volatility	263.77

Integrum AB Series B - Net Assets Trend (2013–2025)

This chart illustrates how Integrum AB Series B's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Integrum AB Series B.

Annual Net Assets for Integrum AB Series B (2013–2025)

The table below shows the annual net assets of Integrum AB Series B from 2013 to 2025. Also explore Integrum AB Series B (INTEG-B) net asset momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	Skr172.01 Million ≈ $18.51 Million	-3.30%
2024-12-31	Skr177.88 Million ≈ $19.14 Million	+24.57%
2023-12-31	Skr142.79 Million ≈ $15.37 Million	-0.52%
2022-12-31	Skr143.53 Million ≈ $15.45 Million	-10.15%
2021-12-31	Skr159.74 Million ≈ $17.19 Million	+557.52%
2020-12-31	Skr24.29 Million ≈ $2.61 Million	+2.39%
2019-12-31	Skr23.73 Million ≈ $2.55 Million	+47.82%
2018-12-31	Skr16.05 Million ≈ $1.73 Million	-10.84%
2017-12-31	Skr18.00 Million ≈ $1.94 Million	+70.90%
2016-12-31	Skr10.53 Million ≈ $1.13 Million	+828.13%
2015-12-31	Skr1.14 Million ≈ $122.14K	+0.09%
2014-12-31	Skr1.13 Million ≈ $122.04K	-62.51%
2013-12-31	Skr3.02 Million ≈ $325.48K	--

Equity Component Analysis

This analysis shows how different components contribute to Integrum AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 3950.8% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	Skr1.87 Million	1.09%
Other Comprehensive Income	Skr-18.34 Million	-10.66%
Other Components	Skr301.09 Million	175.05%
Total Equity	Skr172.01 Million	100.00%

Integrum AB Series B Competitors by Market Cap

The table below lists competitors of Integrum AB Series B ranked by their market capitalization.

Company	Market Cap
Renovaro Biosciences Inc NASDAQ:RENB	$26.19 Million
Tobii AB ST:TOBII	$26.20 Million
Essen Tech Co. Ltd KQ:043340	$26.20 Million
N.D. Rubber Public Company Limited BK:NDR	$26.20 Million
Ravinder Heights Limited NSE:RVHL	$26.18 Million
Thai O.P.P. Public Company Limited BK:TOPP	$26.18 Million
Kisan Telecom Co. Ltd KQ:035460	$26.18 Million
Murray International Trust LSE:MYI	$26.18 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Integrum AB Series B's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 177,875,000 to 172,007,000, a change of -5,868,000 (-3.3%).
Net loss of 46,337,000 reduced equity.
New share issuances of 37,933,000 increased equity.
Other comprehensive income increased equity by 2,751,551.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-46.34 Million	-26.94%
Share Issuances	Skr37.93 Million	+22.05%
Other Comprehensive Income	Skr2.75 Million	+1.6%
Other Changes	Skr-215.55K	-0.13%
Total Change	Skr-	-3.30%

Book Value vs Market Value Analysis

This analysis compares Integrum AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.27x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 30.67x to 1.27x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2013-12-31	Skr0.30	Skr9.35	x
2014-12-31	Skr0.11	Skr9.35	x
2015-12-31	Skr0.11	Skr9.35	x
2016-12-31	Skr1.18	Skr9.35	x
2017-12-31	Skr1.81	Skr9.35	x
2018-12-31	Skr1.28	Skr9.35	x
2019-12-31	Skr1.57	Skr9.35	x
2020-12-31	Skr1.53	Skr9.35	x
2021-12-31	Skr8.79	Skr9.35	x
2022-12-31	Skr7.83	Skr9.35	x
2023-12-31	Skr7.41	Skr9.35	x
2024-12-31	Skr8.34	Skr9.35	x
2025-12-31	Skr7.34	Skr9.35	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Integrum AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -26.94%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -50.71%
• Asset Turnover: 0.45x
• Equity Multiplier: 1.18x
Recent ROE (-26.94%) is above the historical average (-28.24%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	56.82%	9.05%	2.20x	2.86x	Skr1.42 Million
2014	0.02%	0.00%	2.31x	5.66x	Skr-113.22K
2015	0.02%	0.00%	1.21x	8.96x	Skr-113.30K
2016	-54.54%	-32.26%	0.90x	1.88x	Skr-6.80 Million
2017	-101.97%	-120.99%	0.58x	1.47x	Skr-20.16 Million
2018	-153.16%	-109.50%	0.90x	1.55x	Skr-26.19 Million
2019	-66.11%	-58.65%	0.83x	1.36x	Skr-18.06 Million
2020	-8.81%	-4.97%	1.16x	1.53x	Skr-4.57 Million
2021	13.32%	38.17%	0.31x	1.13x	Skr5.30 Million
2022	-11.27%	-21.79%	0.45x	1.15x	Skr-30.53 Million
2023	2.82%	3.87%	0.63x	1.15x	Skr-10.25 Million
2024	-17.34%	-33.87%	0.45x	1.14x	Skr-48.64 Million
2025	-26.94%	-50.71%	0.45x	1.18x	Skr-63.54 Million

Industry Comparison

This section compares Integrum AB Series B's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $773,085,954
Average return on equity (ROE) among peers: -68.53%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Integrum AB Series B (INTEG-B)	Skr174.19 Million	56.82%	0.14x	$26.19 Million
Acarix A/S (ACARIX)	$38.17 Million	-125.99%	0.27x	$26.71 Million
Arcoma AB (ARCOMA)	$40.83 Million	-24.05%	0.67x	$11.70 Million
Bactiguard Holding AB (publ) (BACTI-B)	$386.69 Million	4.20%	0.66x	$51.95 Million
BICO Group AB (BICO)	$6.80 Billion	-3.37%	0.43x	$165.40 Million
Boule Diagnostics AB (BOUL)	$169.99 Million	17.80%	0.65x	$10.41 Million
CellaVision AB (CEVI)	$183.52 Million	28.78%	0.20x	$418.90 Million
Clinical Laserthermia Systems AB (publ) (CLS-B)	$43.53 Million	-183.31%	0.33x	$9.40 Million
Chordate Medical Holding AB (CMH)	$29.55 Million	-46.39%	0.39x	$29.05K
C-Rad AB (publ) (CRAD-B)	$29.82 Million	-34.38%	0.50x	$119.27 Million
Duearity AB (DEAR)	$6.06 Million	-318.56%	0.99x	$331.97K

About Integrum AB Series B

ST:INTEG-B Sweden Medical Devices

Market Cap

$26.19 Million

Skr243.36 Million SEK

Market Cap Rank

#24318 Global

#466 in Sweden

Share Price

Skr9.35

Change (1 day)

+0.32%

52-Week Range

Skr6.96 - Skr15.64

All Time High

Skr102.00